Introduction. The objective of the study was to explore the role of a genetic variant of angiotensinogen (AGT), M235T, as an independent risk factor for acute myocardial infarction (AMI) and to investigate the possible association with the severity of coronary artery disease (CAD), estimated on the basis of the number of coronary stenoses and critical arterial occlusions. Patients and methods. 123 AMI patients were compared to 144 healthy controls. AGT genotypes were determined by PCR. Results. A significant association was found between AGT M235T polymorphism and AMI (p = .021). By logistic regression, the TT genotype appeared to confer 1.9-fold increased risk for AMI in both the univariate and the multivariate model. The frequencies of the TT genotype and T allele increased with the number of stenoses in coronary vessels. Moreover, the TT genotype and the T allele were more frequent in the subgroup of patients with stenoses in at least four coronary vessels than in other patients, including subjects with one-to three-vessel disease. Furthermore, the TT genotype and the T allele were significantly more frequent in patients with critical arterial occlusions (> 90%) than in subjects without critical stenoses. Conclusions. The AGT M235T polymorphism associates with AMI risk and influences CAD severity.
Introduction
The renin-angiotensin system (RAS) plays a central role in arterial blood pressure regulation, and has been incriminated in the pathogenesis of acute myocardial infarction (AMI). Consequently each component of this system represents a potential candidate in the etiology of AMI. Angiotensinogen (AGT) is a liver protein that interacts with renin to produce angiotensin I, the pro-hormone of angiotensin II (Ang II). Ang II is the major effector molecule of RAS, acting by vasoconstricting arteries and particularly coronary vessels, by activating the sympathetic nervous system, and by stimulating fibroblast proliferation; moreover, Ang II may have direct toxic effects on myocardial cells. 1 The AGT gene, located on chromosome 1q41-qter, encodes AGT. There is only one haplotype block at the AGT locus, and all common single nucleotide polymorphisms identified appear to be in complete linkage disequilibrium with the most intensively studied M235T polymorphism. 2 The molecular variant (M235T) of the AGT gene, encoding a threonine instead of a methionine at residue 235 of the mature protein, has been associated with a higher plasma AGT levels in patients homozygous for the T allele and occurs among various ethnic populations. 3 Although the functional variant has not yet been definitively identified, the homozygous TT genotype has been associated with a greater risk of AMI, [4] [5] [6] whereas other studies reported no association. 7, 8 Marked ethnic differences in the frequency of the T allele, small sample sizes and genotyping or phenotyping errors could partly account for discrepancies among these gene-disease association studies.
Because AMI frequently occurs suddenly without any preceding clinical symptoms, the prediction of AMI is clinically of great importance. The principal element of the pathogenesis of AMI is the rupture of coronary atherosclerotic plaques rather than the gradual progression of atherosclerosis to complete occlusion. 9 Identification of factors concerned with plaque rupture should therefore facilitate the prediction of the risk of AMI. The efficacy of angiotensin-converting enzyme (ACE) inhibition and Ang II receptor blockade demonstrate the important role of RAS in the genesis of coronary arteriosclerosis and its related disorders. 10 In the present study, we explored the role of the genetic variant M235T of AGT as an independent risk factor for AMI. We also investigated the possible association of AGT M235T with the severity of coronary artery disease (CAD), estimated on the basis of the number of coronary stenoses and critical arterial occlusions in a Tunisian population.
Methods

Study population
One hundred and twenty-three genetically unrelated Tunisian patients with AMI were recruited from the department of Cardiology of Rabta Hospital (Tunis, Tunisia). The mean age was 62.3 ± 11.8 years. AMI was defined according to the World Health Organization criteria based on symptoms, ECG findings and cardiac enzyme abnormalities. Cardiac catheterization and coronary angiography were performed according to the standard procedures. Coronary angiograms were obtained from multiple projections and the degree of stenosis was quantitatively analyzed. All enrolled patients had angiographically confirmed CAD with 50% or more diameter stenosis of at least one major coronary vessel. The severity of CAD was also estimated by calculating the Gensini score. 11, 12 It was defined by the number of diseased coronary arteries: one-vessel disease (1VD), twovessel disease (2VD), three-vessel disease (3VD), or four-vessel disease (4VD).
Family history, cardiovascular risk factors and current treatment were obtained from each patient using a standard questionnaire. Hypertension was defined as the presence of elevated systolic (> 140 mmHg) and/or diastolic (> 90 mmHg) blood pressure and/or the current use of antihypertensive drugs. The body mass index (BMI) was calculated as weight divided by height. 2 One hundred and fourty-four healthy people (mean age 60.4 ± 10.3 years) matched for sex, age and geographic origin were enrolled as healthy controls. They came from a population of genetically unrelated friends of the patients. This study was approved by the hospital ethical committee, and informed consent was obtained from all healthy controls and patients before their enrolment.
Biochemical measurements
Plasma glucose concentration was evaluated using an enzymatic assay (glucose oxidase, Randox, Antrim, UK), total cholesterol and triglycerides by enzymatic methods using Randox reagents; LDL-and HDL-cholesterol were determined as described by Smaoui et al. 13 AGT genotype determination Genomic DNA was extracted using a standard phenol-chloroform technique from 10 ml blood samples. The AGT M235T genotype was determined by PCR amplification followed by digestion with restriction enzyme Tth111I according to the described method. 14
Statistical analysis
All statistics were carried out using Software Package for Social Sciences (SPSS) version 11.0 (SPSS, Chicago, IL, USA). Allelic and genotypic frequencies were analyzed with the χ 2 test, univariate and multivariate logistic regression. Odds ratios (OR) and 95% confidence interval (CI) were calculated according to Woolf's method. A p value < .05 was considered statistically significant.
Results
Characteristics of the study groups
Clinical and biochemical parameters of the analyzed groups are shown in Table 1 . Smoking, hypertension, and diabetes were significantly higher in AMI patients compared with controls. Higher BMI and levels of triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol and fasting glucose were also shown in AMI patients group. The patients with 1VD were the most frequent (33.3%), and approximately 80.5 % of patients had a critical arterial occlusion (> 90%) in coronary vessels.
Genotype distribution and allele frequencies of AGT M235T polymorphism
The distribution of AGT genotypes was in agreement with the Hardy-Weinberg equilibrium. Genotype frequencies of AGT M235T polymorphism differed significantly between AMI patients and controls (p = .021) ( Table 1 ). Compared to the healthy controls, the frequencies of the TT genotype and T allele were significantly higher in AMI patients. OR of 1.9 and 1.68 were calculated for the TT genotype and the T allele (Table 1) . Conversely, the MM genotype as well as the M allele were associated with decreased risk of AMI (MM: OR = 0.53, 95% CI, 0.3-0.91, p = .020; M: OR = 0.56; 95 % CI: 0.42-0.84, p = .003). By multivariate logistic regression model, TT genotype and hypertension are independent risk factors for AMI (TT: OR = 1.98; 95 % CI: 1.81-3.65, p = .013 and HTA: OR = 5.3; 95 % CI: 3.81-9.01, p < .001) (adjusted for age, sex, smoking, hypertension, dyslipidemia, BMI and number of stenosed vessels). Furthermore, the presence of a significant interaction between the TT genotype and hypertension (p = 0.047) was associated with increased risk of AMI. 
AGT M235T gene polymorphism and number of coronary stenoses
Because the number of patients with 2VD and 3VD was relatively small, we performed the stratification of analyzed patients into consequent subgroups: 1) 1VD: patients with 1VD (n = 41); 2) 2VD and more: patients with multi-vessel disease with stenoses in two or more coronary vessels (n = 82); 3) 3VD and more: patients with multi-vessel disease with stenoses in three or more vessels (n = 50); and 4) 4VD and more: patients with multi-vessel disease with stenoses in four or more coronary vessels (n = 31) ( Table 2 ). We found that the frequencies of the TT genotype and the T allele increased in the subsequent subgroups, in particular being the most elevated in the subgroup of patients with stenoses in at least four coronary vessels. We also found significant differences between subgroups of patients with at least four coronary stenoses (subgroup 4) and patients with 1VD (subgroup 1) for the T allele, the MM genotype and the M allele. These data were confirmed by the univariate logistic regression model (Table 2 ).
Furthermore, we compared a subgroup of patients with stenoses in at least four coronary vessels with other patients, including subjects with 1VD, 2VD and 3VD. Age, sex, diabetes, BMI and hypertension did not differentiate these two subgroups. The T allele and TT genotype were These results may indicate the presence of an association between the T allele, or TT genotype, and multi-vessel disease in the analyzed population (T: OR = 2.5, 95% CI: 1.34-4.64, p = .004 and TT: OR = 2.4, 95% CI: 1.01-5.72, p = .004) in both univariate and multivariate logistic regression analysis. The M allele and MM genotype were significantly more frequent in the subgroup of patients with 1VD+2VD+3VD than in patients with at least four coronary stenoses (MM: OR = 0.08, 95% CI: 0.01-0.59, p = .013 and M: OR = 0.4, 95% CI: 0.21-0.74, p = .004).
AGT M235T gene polymorphism and critical arterial occlusion
Finally, we analyzed the frequencies of genotypes and alleles of the AGT M235T gene polymorphism in the subgroups of patients differentiated with respect to the presence or absence of critical stenoses (> 90%) in coronary vessels ( Table 3 ). We showed that the TT genotype and T allele were significantly more frequent in the subgroup of patients with critical arterial occlusions than in the patients without critical stenoses in the univariate logistic regression model (TT: OR = 15.6, 95% CI: 2.02-120.2, p < .001 and T: OR = 5.6, 95% CI: 2.7-11.7, p < .001). Both the MM genotype and M allele were significantly more frequent in the subgroup of patients without critical stenoses ( Table 3 ). The results may suggest the presence of an association between the AGT M235T gene polymorphism and the critical stenoses of coronary arteries.
Discussion
Looking beyond the classical risk factors for cardiovascular diseases such as hypertension, dyslipidemia, diabetes and smoking, many investigators have recently pursued the study of genetic factors in the RAS to predict the development of AMI. In the present study, we found that AGT M235T gene polymorphism is a genetic risk factor for AMI. The risk of developing AMI was higher for the TT genotype and T allele compared to the MM genotype or M allele. Furthermore, multiple logistic regression analysis revealed that the TT genotype was a risk factor for AMI independently from sex and other clinical features. Although some studies support our results, 4,6 others failed to show such an association. 7, 8 Several possible factors may contribute to these discrepancies such as the genetic and environmental heterogeneity among the different ethnic groups. 15 Interestingly, we found that hypertension was the most important risk factor for AMI in our population. Moreover, the presence of the TT genotype and hypertension both together increased the risk for AMI (p = .047). This association was previously described in other studies but with conflicting results. 3, 7 In three meta-analyses, the TT genotype was associated with increased risk for hypertension in Caucasians with an OR for TT vs. MM of 1.31, in the first meta-analysis, 15 an OR for T vs. M of 1.20 (95% CI: 1.11-1.29) in the second meta-analysis, 16 and an OR for TT vs. MM of 1.19 (95% CI: 1.10-1.30) in the third meta-analysis. 17 Another recent meta-analysis suggested that the TT genotype is rather associated with a decreased risk for hypertension (TT vs. MM: OR = 0.52; 95% CI: 0.28-0.96). 18 AGT concentration is a limiting factor for Ang II generation, 19 thus its increased amounts may dramatically increase Ang II levels, potentially promoting atherosclerosis 20 or modulating the severity of CAD. 21 It remains unclear whether the AGT M235T gene polymorphism has a functional effect on the progression of the CAD phenotype; therefore, in the present work we investigated the possible associations of this polymorphism and the severity of CAD, estimated especially on the basis of the number of coronary stenoses and of the critical arterial occlusions observed during coronary angiography. Our results show that the genotype TT may influence the severity of CAD through the generation of numerous and critical atherosclerotic lesions. Jeunemaitre et al. 4 reported an association of the T allele with the extent of coronary lesions. Olivieri et al. 22 found that the TT genotype appeared to confer 1.9-fold increased risk for AMI in patients with multivessel disease in an Italian population. Pereira et al. 23 showed that presence of the TT genotype was associated with the severity of CAD independently of other cardiovascular risks. But no significant association was found by Goldenberg et al. 24 and by Nair et al. 7 between T homozygosity and the severity of the disease.
AGT is converted by renin into Ang I and further cleaved to Ang II by ACE. Being the main Ang II precursor, AGT is an important determinant of Ang II level in both serum and tissues. 25 The physiological effects of Ang II are mediated by a final common pathway, through Ang II binding to specific receptors located on the cell membrane. These effects seem to parallel RAS influence on the other mechanisms of coronary atherosclerosis development, including vascular smooth muscle proliferation, intimal fibrosis, chemoattraction of inflammatory cells, increase of plasminogen activator inhibitor-1 expression, and lipid accumulation/ atherogenecity. 26 Moreover, RAS impairs NO release and activity through bradykinin degradation by ACE and oxidative stress; 27 more precisely, Ang II generates oxidative stress through the stimulation of NADH/NADPH oxidase in vascular smooth muscle cells and endothelial cells. 28 NO plays important roles in inhibiting platelet activation and adhesion to the endothelium 29 as well as monocyte adhesion. In addition, other authors reported a deficiency in both basal and stimulated NO activity in patients with coronary spastic angina, indicating pivotal roles of NO in the pathogenesis of coronary artery spasm, 30 which is now considered an early stage of coronary atherosclerosis. 31 In conclusion, AGT M235T polymorphism is associated with AMI risk and influences in severity of CAD. However, due to our limited sample size our findings require confirmation in larger cohorts.
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